Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozorakimab in Symptomatic COPD With a History of Exacerbations (MIRANDA)
NCT06040086Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Sep 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06040086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040086.